Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

PURPOSE: We examined the role of ERBB2 activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. DESIGN: ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320312/
https://ncbi.nlm.nih.gov/pubmed/30314968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1544
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg